Clinical Trials Results - National Cancer Institute

In English \| En español

Search


	Clinical Trials Search Results

Page Options

E-Mail This Search

Clinical Trial Questions?

Get Help:

1-800-4-CANCER

	Quick Links


	Help Using the NCI Clinical Trials Search Form Educational Materials About Clinical Trials About NCI's Cancer Clinical Trials Registry Dictionary of Cancer Terms NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 34 for your search:

Drug:  idarubicin
Find trials that include:  Any drugs shown
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 55
Sponsor: Other
Protocol IDs: GMALL02, NCT00198978

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL01, NCT00198991

Efficacy of G-CSF-Priming in Elderly AML Patients

Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: AML-elderly 01/99 Trial, NCT00199147

AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia

Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: MK1-192, NCT00180128

Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)

Phase: Phase IV
Type: Treatment
Status: Active
Age: 0 to 75
Sponsor: Other
Protocol IDs: LPA 2005, NCT00408278

LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: PETHEMA-LAM07, NCT01041040

Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: MYFLAI07, NCT00909168

Phase III Randomized Study of Arsenic Trioxide and Tretinoin Versus Combination Chemotherapy Comprising Tretinoin, Idarubicin, Mitoxantrone Hydrochloride, Methotrexate, and Mercaptopurine for Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: GIMEMA-DSL-APL0406, EUDRACT-2006-006188-22, APL0406, EU-20725, NCT00482833

A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML)

Phase: Phase III
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: NILG-AML 02/06, NCT00495287

10.

Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old

Phase: Phase III
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: CHUBX 2007/13, NCT00590837

11.

Phase III Study of Risk-Adapted Induction Chemotherapy, Risk-Adapted Consolidation Combination Chemotherapy Including Arsenic Trioxide, and Maintenance Combination Chemotherapy in Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 21
Sponsor: NCI
Protocol IDs: COG-AAML0631, COG-AAML0631, AAML0631, NCT00866918

12.

Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma

Phase: Phase III
Type: Treatment
Status: Active
Age: 6 months to 21 years
Sponsor: Other
Protocol IDs: CWS-2007-HR, 4033024 (BfArM), 293/2007AMG1 (Ethikkommission), 2007-001478-10 (EUDRACT), A2007/14 (Kinderkrebsstiftung), 498 (Krebsstudienregister), NCT00876031

13.

Phase III Partially Randomized Study of Combination Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 18
Sponsor: Other
Protocol IDs: CCLG-ALLR3, CCLG-ALLR3, ISCRTN-45724312, EUDRACT-2004-000052-16, EU-20938, NCT00967057

14.

Study of Chemotherapy in Combination With All-Trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation

Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: AMLSG 09-09, NCT00893399

15.

Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Nº EudraCT: 2005-004370-24, IIS-VEL-EU-070/26866138CAN2015, NCT00651781

16.

Phase I/II Randomized Study of Clofarabine, Cytarabine, and Idarubicin in Patients With Previously Untreated Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor:
Protocol IDs: EORTC-06061, EORTC-06061, EU-20905, EudraCT-2006-004912-28, GIMEMA-AML-14A, NCT00838240

17.

Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 65 and over
Sponsor: Other
Protocol IDs: PANOBIDARA, NCT00840346

18.

Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: T-CID, NCT00124813

19.

Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CAI, NCT00126321

20.

Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: IELSG21, NCT00210366

21.

Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)

Phase: Phase II
Type: Treatment
Status: Active
Age: Over 55
Sponsor: Other
Protocol IDs: CSTI571ADE10, GMALL-STI571-ELDERLY-01/02, NCT00199186

22.

Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)

Phase: Phase II
Type: Treatment
Status: Active
Age: 15 to 75
Sponsor: Other
Protocol IDs: 2006-0813, NCT00422591

23.

Phase II Study of Combination Chemotherapy With or Without Imatinib Mesylate and/or Peripheral Blood Stem Cell Transplantation in Patients With Acute Lymphoblastic Leukemia

Phase: Phase II
Type: Treatment
Status: Active
Age: 15 to 60
Sponsor: Other
Protocol IDs: GIMEMA-LAL0904, EUDRACT-2004-001738-11, EU-20714, NCT00458848

24.

FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML

Phase: Phase II
Type: Treatment
Status: Active
Age: 15 to 60
Sponsor: Other
Protocol IDs: C-007A, NCT00559221

25.

Phase II Pilot Study of Bortezomib and Reinduction Chemotherapy in Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI
Protocol IDs: COG-AAML07P1, AAML07P1, NCT00666588

Select All on Page

Help with Results

A Service of the National Cancer Institute